Skip to main content
OpenTrials
Completed

NCT Number: NCT03836469

Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil

RELANCE is a large multi-institutional study that aims to retrospectively collect information about diagnostic, treatment and outcome of patients diagnosed with locally advanced NSCLC in Brazil. It is hypothesized that there is a great heterogeneity in treatment patterns owing to inequities in access to adequate staging methods, optimal treatment and multidisciplinary teams in Brazil.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer, Non-small Cell Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

AC Camargo

São Paulo, Brazil

About this study

RELANCE study will collect sociodemographic and clinical data of patients diagnosed with locally advanced NSCLC in the period of January 2015 and Jun 2019 in the participating institutions. Socio-demographic characteristics, clinicopathological features, treatments patterns and outcomes will be recovered from medical charts. Disease status and survival data will be collected up to the last date of follow-up June 2021.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 years or older;
  • Histologically or cytological diagnosis of NSCLC in the period of January 2015 to December 2016;
  • Locally Advanced NSCLC defined as clinical stage IIIA and IIIB according to 7th Edition TNM Staging System;
  • Any NSCLC histological subtype and molecular mutation;
  • Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;
  • Patients assigned by treating physician to any therapy or palliative care;
  • Access to patient medical chart for data collection.

Exclusion criteria

  • Small cell lung cancer and non-invasive NSCLC;
  • Synchronic NSCLC or second primary tumour in the last 5 years (except non-melanoma skin cancer).

Treatment and study plan

Primary outcomes

  1. Overall survival

    Time frame: Up to June 30, 2018

    defined as time from diagnosis to death of any cause;

Secondary outcomes

  1. Progression free survival

    Time frame: Up to June 30, 2018

    defined as time from any line of treatment to progression of the disease or death of any cause

  2. Time to next treatment

    Time frame: Up to June 30, 2018

    defined as time from start of the any treatment to the beginning of a second therapy

Sponsors and collaborators

Lead sponsor

Latin American Cooperative Oncology Group

Other

Collaborators

  • AstraZeneca

Registry information

Acronym: RELANCE

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Feb 11, 2019
Registry last updated
Feb 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.